Gemma Martinez-Rivas

Gemma Martinez-Rivas

Auto-generated profile, based on publicly available information

Gemma Martinez-Rivas

CNRS UMR7276/INSERM U1262, University of Limoges, CRIBL lab, team 3 BioPIC, Limoges, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GMGemma Martinez-Rivas
Gemma Martinez-Rivas
MAMaria Victoria Ayala
Maria Victoria Ayala
SBSebastien Bender
Sebastien Bender
GCGilles Roussine Codo
Gilles Roussine Codo
WSWeronika Karolina Swiderska
Weronika Karolina Swiderska
CSchristophe sirac
christophe sirac
Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better understanding this disease. Here, we develop a transgenic mouse model producing a human AL LC. We show that the soluble full length LC is not toxic but a single injection of pre-formed amyloid fibrils or an unstable fragment of the LC leads to systemic amyloid deposits associated with early cardiac dysfunction. AL fibrils in mice are highly similar to that of human, arguing for a conserved mechanism of amyloid fibrils formation. Overall, this transgenic mice closely reproduces human cardiac AL amyloidosis and shows that a partial degradation of the LC is likely to initiate the formation of amyloid fibrils in vivo, which in turn leads to cardiac dysfunction. This is a valuable model for research on AL amyloidosis and preclinical evaluation of new therapies.